Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.EnzymeRx, a clinical stage biotechnology company, has appointed Elizabeth John as its new vice president of manufacturing. The company also named John Zhang as its new vice president of preclinical R&D.
Subscribe to our email newsletter
Dr John has most recently served as head of R&D at Centegen, a biotechnology start-up. She brings 17 years of experience in the manufacture of biologics and the regulation of biologics manufacturing to EnzymeRx, and in her career has contributed to multiple investigational new drug applications, managed drug development programs, and has interacted closely with the FDA and foreign regulatory agencies, said EnzymeRx.
Dr Zhang most recently served as director of preclinical pharmacology and toxicology at Pharmacopeia until its acquisition by Ligand Pharmaceuticals. He was previously associate director and department head of toxicology and drug metabolism and pharmacokinetics at Enzon Pharmaceuticals, and has additionally managed toxicology programs for several projects at Hoffmann-La Roche and Abbott Laboratories.
Tony Fiorino, president and CEO of EnzymeRx, said: “We are excited to welcome these two new members of the EnzymeRx team. Both have already made important contributions to EnzymeRx and will help us accelerate the development of uricase-PEG 20.”